UY32744A - Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 - Google Patents

Derivados de 2-carboxamida-7-piperazinil-benzofurano 774

Info

Publication number
UY32744A
UY32744A UY0001032744A UY32744A UY32744A UY 32744 A UY32744 A UY 32744A UY 0001032744 A UY0001032744 A UY 0001032744A UY 32744 A UY32744 A UY 32744A UY 32744 A UY32744 A UY 32744A
Authority
UY
Uruguay
Prior art keywords
carboxamida
piperazinil
benzofurano
derivatives
compounds
Prior art date
Application number
UY0001032744A
Other languages
English (en)
Inventor
Nordvall Gunnar
Andersson Johan
Helena Gybaeck
Johansson Anh
Christian Erik Linde
Jonas Malmstroem
Weigelt Tatjana
Terp Gitte
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32744A publication Critical patent/UY32744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I), a composiciones farmacéuticas que los contienen, al uso de dichos compuestos en terapia, por ejemplo, en el tratamiento de trastornos cognitivos, así como a nuevos intermedios útiles en su preparación.
UY0001032744A 2009-06-30 2010-06-29 Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 UY32744A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22165709P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
UY32744A true UY32744A (es) 2011-01-31

Family

ID=43381415

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032744A UY32744A (es) 2009-06-30 2010-06-29 Derivados de 2-carboxamida-7-piperazinil-benzofurano 774

Country Status (14)

Country Link
US (2) US8367676B2 (es)
EP (1) EP2448934B1 (es)
JP (1) JP5767211B2 (es)
KR (1) KR20120110000A (es)
CN (1) CN102482264B (es)
AR (1) AR077301A1 (es)
AU (1) AU2010266753B2 (es)
BR (1) BRPI1014222A2 (es)
CA (1) CA2765475A1 (es)
MX (1) MX2011013449A (es)
RU (1) RU2011152516A (es)
TW (1) TW201103922A (es)
UY (1) UY32744A (es)
WO (1) WO2011002405A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
AU2011345381A1 (en) 2010-12-20 2013-06-13 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
CN102993186B (zh) * 2012-12-20 2015-11-18 北京海步国际医药科技发展有限公司 一种新型的哌嗪衍生物
CN105339371A (zh) * 2013-03-07 2016-02-17 葛兰素史密斯克莱有限责任公司 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2021243421A1 (en) * 2020-06-05 2021-12-09 Monash University Dual kinase-bromodomain inhibitors
CN117430574B (zh) * 2023-12-20 2024-03-22 潍坊医学院 一种苯并呋喃衍生物及其制备方法、用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
CA2297825C (en) * 1997-07-25 2006-03-14 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
BR0210411A (pt) 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
WO2003104227A1 (de) * 2002-01-20 2003-12-18 Bayer Healthcare Ag 2-heteroarylcarbonsäureamide
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
WO2005077885A1 (en) 2004-02-06 2005-08-25 Yale University Ruthenium-catalyzed hydroamination of olefins
WO2006062481A1 (en) 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
WO2007053093A1 (en) 2005-11-04 2007-05-10 Astrazeneca Ab Chroman compounds as 5 ht1b antagonists
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
EP2094686A1 (en) 2006-09-26 2009-09-02 Glaxo Group Limited 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl]ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.
CA2668959A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774

Also Published As

Publication number Publication date
TW201103922A (en) 2011-02-01
US8859534B2 (en) 2014-10-14
US8367676B2 (en) 2013-02-05
MX2011013449A (es) 2012-02-13
CN102482264B (zh) 2015-10-07
CN102482264A (zh) 2012-05-30
AU2010266753B2 (en) 2013-08-08
WO2011002405A1 (en) 2011-01-06
EP2448934B1 (en) 2014-05-21
US20130296296A1 (en) 2013-11-07
BRPI1014222A2 (pt) 2017-05-16
RU2011152516A (ru) 2013-08-10
EP2448934A4 (en) 2012-12-05
KR20120110000A (ko) 2012-10-09
AR077301A1 (es) 2011-08-17
EP2448934A1 (en) 2012-05-09
JP5767211B2 (ja) 2015-08-19
JP2012532125A (ja) 2012-12-13
CA2765475A1 (en) 2011-01-06
US20100331341A1 (en) 2010-12-30
AU2010266753A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120264A (es) Compuestos
ECSP11011517A (es) Compuestos antivirales
CO6351783A2 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
BRPI0910388A2 (pt) agentes terapêutico antivirais.
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112012029647A2 (pt) novos derivados de pirimidinas
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CO6341625A2 (es) Derivados de indol como agentes anticáncer
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
CO6640201A2 (es) Moduladores de crth2
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
DE602007005387D1 (de) Ptors
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130124